Abstract | BACKGROUND: METHODS: Eligibility criteria included incurable ACC, any number of prior therapies but without an anthracycline, unidimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and ejection fraction within normal limits. Patients with stable disease for ≥9 months were excluded. Patients received bortezomib 1.3 mg/m(2) by intravenous (IV) push on Days 1, 4, 8, and 11, every 21 days until progression. Doxorubicin 20 mg/m(2) IV on Days 1 and 8 was added at the time of progression. RESULTS: Twenty-five patients were enrolled, of whom 24 were eligible; the most common distant metastatic sites were the lung (n = 22) and the liver (n = 7). There was no objective response with single-agent bortezomib; best response was stable disease in 15 (71%) of 21 evaluable patients. The median progression-free survival and overall survival were 6.4 months and 21 months, respectively. Of 10 evaluable patients who received bortezomib plus doxorubicin, 1 had a partial response, and 6 had stable disease. The most frequent toxicity with bortezomib was grade 3 sensory neuropathy (16%). With bortezomib plus doxorubicin, serious toxicities seen more than once were grade 3-4 neutropenia (n = 3) and grade 3 anorexia (n = 2). CONCLUSIONS:
Bortezomib was well tolerated and resulted in disease stabilization in a high percentage of patients but no objective responses. The combination of bortezomib and doxorubicin was also well tolerated and may warrant further investigation in ACC.
|
Authors | Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, Rita S Axelrod, Ronald C Deconti, Arlene A Forastiere |
Journal | Cancer
(Cancer)
Vol. 117
Issue 15
Pg. 3374-82
(Aug 01 2011)
ISSN: 1097-0142 [Electronic] United States |
PMID | 21246525
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2011 American Cancer Society. |
Chemical References |
- Boronic Acids
- Pyrazines
- Bortezomib
- Doxorubicin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Boronic Acids
(administration & dosage)
- Bortezomib
- Carcinoma, Adenoid Cystic
(drug therapy, pathology)
- Disease Progression
- Doxorubicin
(administration & dosage)
- Female
- Head and Neck Neoplasms
(drug therapy, pathology)
- Humans
- Liver Neoplasms
(drug therapy, pathology, secondary)
- Lung Neoplasms
(drug therapy, pathology, secondary)
- Male
- Middle Aged
- Neoplasm Metastasis
- Pyrazines
(administration & dosage)
- Recurrence
- Survival Analysis
|